Treating ALK-positive non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Genomic alterations, including EGFR mutations and ALK rearrangements, are key drivers in non-small cell lung cancer (NSCLC).
• ALK rearrangements have led to the development of targeted therapies, specifically ALK tyrosine kinase inhibitors (TKIs), revolutionizing personalized NSCLC treatment.
• Crizotinib, the first ALK TKI, demonstrated superiority over chemotherapy but faced challenges with acquired resistance and limited central nervous system (CNS) efficacy.

Purpose of the Study:

• To review the current understanding of ALK-positive NSCLC biology.
• To discuss the landscape of available ALK tyrosine kinase inhibitors (TKIs) for NSCLC treatment.
• To examine clinical practice issues and optimal sequencing strategies for ALK inhibitors in NSCLC.

Main Methods:

• Review of published literature on ALK-positive NSCLC.
• Analysis of clinical trial data for approved and investigational ALK inhibitors.
• Discussion of resistance mechanisms and CNS efficacy of ALK TKIs.

Main Results:

• Four ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib) are FDA/EMA approved, with more agents under investigation.
• Recent Phase III trials indicate superior efficacy of alectinib compared to crizotinib in the first-line setting for ALK-rearranged NSCLC.
• Alectinib demonstrates significant efficacy even in patients with CNS involvement, addressing a key limitation of earlier TKIs.

Conclusions:

• ALK inhibitors represent a significant advancement in personalized medicine for NSCLC.
• Novel ALK TKIs offer improved potency and CNS penetration compared to crizotinib.
• Optimal frontline treatment selection and sequencing of ALK inhibitors remain critical considerations for maximizing patient outcomes in ALK-positive NSCLC.